The Effect of Tranexamic Acid on Operative and Postoperative Blood Loss in Transforaminal Lumbar Interbody Fusions
Copyright © 2022 Elsevier Inc. All rights reserved..
OBJECTIVE: The purpose of this retrospective cohort study was to evaluate the effect of tranexamic acid (TXA) on reducing perioperative blood loss and length of stay after transforaminal lumbar interbody fusion (TLIF). Spine surgery is associated with the potential for significant blood loss, and adequate hemostasis is essential to visualizing crucial structures during the approach and procedure. Although TXA use has been extensively studied in the pediatric and adult spinal deformity literature, there is a dearth of literature on its efficacy in reducing blood loss for patients who undergo 1- to 3-level TLIF.
METHODS: All patients requiring 1- to 3-level TLIF who received a preoperative loading dose of TXA were grouped and compared with patients who didn't receive TXA. Demographic, surgical, and laboratory values were collected and analyzed. Continuous and categorical variables were analyzed with χ2, Kruskal-Wallis, or analysis of variance tests, depending on normality and data type. Multiple linear regressions were developed to determine independent predictors of the estimated blood loss (EBL), total blood loss, drain output, and length of stay. Statistical significance was set at P < 0.05.
RESULTS: Patients who received preoperative TXA had more comorbidities (P = 0.006), longer surgery length (P < 0.001), and longer length of stay (P = 0.004). TXA was independently associated with a decreased day 0, 1, 2, and total drain output (P < 0.001, P = 0.001, P = 0.007, P < 0.001, respectively), but was not associated with a change in EBL, total blood loss, or length of stay.
CONCLUSIONS: The application of preoperative TXA for patients undergoing 1- to 3-level TLIF reduced drain output in the first 2 postoperative days, but it did not affect hospital length of stay, total blood loss, or EBL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:166 |
|---|---|
| Enthalten in: |
World neurosurgery - 166(2022) vom: 28. Okt., Seite e443-e450 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kanhere, Arun P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6T84R30KC1 |
|---|
| Anmerkungen: |
Date Completed 05.10.2022 Date Revised 14.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.wneu.2022.07.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343603373 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343603373 | ||
| 003 | DE-627 | ||
| 005 | 20231226020832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.wneu.2022.07.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343603373 | ||
| 035 | |a (NLM)35840090 | ||
| 035 | |a (PII)S1878-8750(22)00957-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kanhere, Arun P |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effect of Tranexamic Acid on Operative and Postoperative Blood Loss in Transforaminal Lumbar Interbody Fusions |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2022 | ||
| 500 | |a Date Revised 14.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: The purpose of this retrospective cohort study was to evaluate the effect of tranexamic acid (TXA) on reducing perioperative blood loss and length of stay after transforaminal lumbar interbody fusion (TLIF). Spine surgery is associated with the potential for significant blood loss, and adequate hemostasis is essential to visualizing crucial structures during the approach and procedure. Although TXA use has been extensively studied in the pediatric and adult spinal deformity literature, there is a dearth of literature on its efficacy in reducing blood loss for patients who undergo 1- to 3-level TLIF | ||
| 520 | |a METHODS: All patients requiring 1- to 3-level TLIF who received a preoperative loading dose of TXA were grouped and compared with patients who didn't receive TXA. Demographic, surgical, and laboratory values were collected and analyzed. Continuous and categorical variables were analyzed with χ2, Kruskal-Wallis, or analysis of variance tests, depending on normality and data type. Multiple linear regressions were developed to determine independent predictors of the estimated blood loss (EBL), total blood loss, drain output, and length of stay. Statistical significance was set at P < 0.05 | ||
| 520 | |a RESULTS: Patients who received preoperative TXA had more comorbidities (P = 0.006), longer surgery length (P < 0.001), and longer length of stay (P = 0.004). TXA was independently associated with a decreased day 0, 1, 2, and total drain output (P < 0.001, P = 0.001, P = 0.007, P < 0.001, respectively), but was not associated with a change in EBL, total blood loss, or length of stay | ||
| 520 | |a CONCLUSIONS: The application of preoperative TXA for patients undergoing 1- to 3-level TLIF reduced drain output in the first 2 postoperative days, but it did not affect hospital length of stay, total blood loss, or EBL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Blood loss | |
| 650 | 4 | |a Drain output | |
| 650 | 4 | |a Tranexamic acid | |
| 650 | 4 | |a Transforaminal lumbar interbody fusion | |
| 650 | 7 | |a Tranexamic Acid |2 NLM | |
| 650 | 7 | |a 6T84R30KC1 |2 NLM | |
| 700 | 1 | |a Lambrechts, Mark J |e verfasserin |4 aut | |
| 700 | 1 | |a Issa, Tariq Ziad |e verfasserin |4 aut | |
| 700 | 1 | |a Karamian, Brian A |e verfasserin |4 aut | |
| 700 | 1 | |a Hendow, Chelsea J |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Yashas C |e verfasserin |4 aut | |
| 700 | 1 | |a Slota, Paul J |e verfasserin |4 aut | |
| 700 | 1 | |a D'Antonio, Nicholas D |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Ian David |e verfasserin |4 aut | |
| 700 | 1 | |a Canseco, Jose A |e verfasserin |4 aut | |
| 700 | 1 | |a Woods, Barrett I |e verfasserin |4 aut | |
| 700 | 1 | |a Hilibrand, Alan S |e verfasserin |4 aut | |
| 700 | 1 | |a Kepler, Christopher K |e verfasserin |4 aut | |
| 700 | 1 | |a Vaccaro, Alexander R |e verfasserin |4 aut | |
| 700 | 1 | |a Schroeder, Gregory D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World neurosurgery |d 2010 |g 166(2022) vom: 28. Okt., Seite e443-e450 |w (DE-627)NLM197924441 |x 1878-8769 |7 nnns |
| 773 | 1 | 8 | |g volume:166 |g year:2022 |g day:28 |g month:10 |g pages:e443-e450 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.wneu.2022.07.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 166 |j 2022 |b 28 |c 10 |h e443-e450 | ||